Research analysts at StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ – Get Free Report) in a research note issued to investors on Monday. The firm set a “hold” rating on the medical research company’s stock.
Enzo Biochem Price Performance
ENZ stock opened at $1.06 on Monday. The firm has a 50 day simple moving average of $1.10 and a 200-day simple moving average of $1.11. Enzo Biochem has a twelve month low of $0.93 and a twelve month high of $1.50.
Hedge Funds Weigh In On Enzo Biochem
A number of hedge funds have recently added to or reduced their stakes in ENZ. XTX Topco Ltd boosted its holdings in Enzo Biochem by 94.5% in the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after purchasing an additional 13,735 shares during the period. BBR Partners LLC acquired a new position in Enzo Biochem in the third quarter worth $112,000. Geode Capital Management LLC boosted its holdings in Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after purchasing an additional 11,742 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 64,417 shares during the period. Institutional investors and hedge funds own 36.90% of the company’s stock.
Enzo Biochem Company Profile
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Featured Articles
- Five stocks we like better than Enzo Biochem
- What is the Nasdaq? Complete Overview with History
- Survey Reveals: Which States Saw the Biggest Investment Gains in 2024?
- Stock Splits, Do They Really Impact Investors?
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- P/E Ratio Calculation: How to Assess Stocks
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.